div class=ts-pagebutton class=gotoPage data-page=1Page 1button div class=ts-imageimg data-url=oncologypro-educational-portal-for-oncologists-patients-with-advanced-netshtmlpage=1 data-page=1 class=ts-thumb lazyload alt=Page 1: OncologyPRO Educational Portal for Oncologistspatients with advanced NETS after progression on everolimus N 395 Well- or moderately-differentiated neuroendocrine Cabozantinib loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader034vdocumentssitereader034viewer20220504125f893dfa9e106f71164efef7html5thumbnails1jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=2Page 2button div class=ts-imageimg data-url=oncologypro-educational-portal-for-oncologists-patients-with-advanced-netshtmlpage=2 data-page=2 class=ts-thumb lazyload alt=Page 2: OncologyPRO Educational Portal for Oncologistspatients with advanced NETS after progression on everolimus N 395 Well- or moderately-differentiated neuroendocrine Cabozantinib loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader034vdocumentssitereader034viewer20220504125f893dfa9e106f71164efef7html5thumbnails2jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=3Page 3button div class=ts-imageimg data-url=oncologypro-educational-portal-for-oncologists-patients-with-advanced-netshtmlpage=3 data-page=3 class=ts-thumb lazyload alt=Page 3: OncologyPRO Educational Portal for Oncologistspatients with advanced NETS after progression on everolimus N 395 Well- or moderately-differentiated neuroendocrine Cabozantinib loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader034vdocumentssitereader034viewer20220504125f893dfa9e106f71164efef7html5thumbnails3jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=4Page 4button div class=ts-imageimg data-url=oncologypro-educational-portal-for-oncologists-patients-with-advanced-netshtmlpage=4 data-page=4 class=ts-thumb lazyload alt=Page 4: OncologyPRO Educational Portal for Oncologistspatients with advanced NETS after progression on everolimus N 395 Well- or moderately-differentiated neuroendocrine Cabozantinib loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader034vdocumentssitereader034viewer20220504125f893dfa9e106f71164efef7html5thumbnails4jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=5Page 5button div class=ts-imageimg data-url=oncologypro-educational-portal-for-oncologists-patients-with-advanced-netshtmlpage=5 data-page=5 class=ts-thumb lazyload alt=Page 5: OncologyPRO Educational Portal for Oncologistspatients with advanced NETS after progression on everolimus N 395 Well- or moderately-differentiated neuroendocrine Cabozantinib loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader034vdocumentssitereader034viewer20220504125f893dfa9e106f71164efef7html5thumbnails5jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=6Page 6button div class=ts-imageimg data-url=oncologypro-educational-portal-for-oncologists-patients-with-advanced-netshtmlpage=6 data-page=6 class=ts-thumb lazyload alt=Page 6: OncologyPRO Educational Portal for Oncologistspatients with advanced NETS after progression on everolimus N 395 Well- or moderately-differentiated neuroendocrine Cabozantinib loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader034vdocumentssitereader034viewer20220504125f893dfa9e106f71164efef7html5thumbnails6jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=7Page 7button div class=ts-imageimg data-url=oncologypro-educational-portal-for-oncologists-patients-with-advanced-netshtmlpage=7 data-page=7 class=ts-thumb lazyload alt=Page 7: OncologyPRO Educational Portal for Oncologistspatients with advanced NETS after progression on everolimus N 395 Well- or moderately-differentiated neuroendocrine Cabozantinib loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader034vdocumentssitereader034viewer20220504125f893dfa9e106f71164efef7html5thumbnails7jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=8Page 8button div class=ts-imageimg data-url=oncologypro-educational-portal-for-oncologists-patients-with-advanced-netshtmlpage=8 data-page=8 class=ts-thumb lazyload alt=Page 8: OncologyPRO Educational Portal for Oncologistspatients with advanced NETS after progression on everolimus N 395 Well- or moderately-differentiated neuroendocrine Cabozantinib loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader034vdocumentssitereader034viewer20220504125f893dfa9e106f71164efef7html5thumbnails8jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=9Page 9button div class=ts-imageimg data-url=oncologypro-educational-portal-for-oncologists-patients-with-advanced-netshtmlpage=9 data-page=9 class=ts-thumb lazyload alt=Page 9: OncologyPRO Educational Portal for Oncologistspatients with advanced NETS after progression on everolimus N 395 Well- or moderately-differentiated neuroendocrine Cabozantinib loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader034vdocumentssitereader034viewer20220504125f893dfa9e106f71164efef7html5thumbnails9jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=10Page 10button div class=ts-imageimg data-url=oncologypro-educational-portal-for-oncologists-patients-with-advanced-netshtmlpage=10 data-page=10 class=ts-thumb lazyload alt=Page 10: OncologyPRO Educational Portal for Oncologistspatients with advanced NETS after progression on everolimus N 395 Well- or moderately-differentiated neuroendocrine Cabozantinib loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader034vdocumentssitereader034viewer20220504125f893dfa9e106f71164efef7html5thumbnails10jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=11Page 11button div class=ts-imageimg data-url=oncologypro-educational-portal-for-oncologists-patients-with-advanced-netshtmlpage=11 data-page=11 class=ts-thumb lazyload alt=Page 11: OncologyPRO Educational Portal for Oncologistspatients with advanced NETS after progression on everolimus N 395 Well- or moderately-differentiated neuroendocrine Cabozantinib loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader034vdocumentssitereader034viewer20220504125f893dfa9e106f71164efef7html5thumbnails11jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=12Page 12button div class=ts-imageimg data-url=oncologypro-educational-portal-for-oncologists-patients-with-advanced-netshtmlpage=12 data-page=12 class=ts-thumb lazyload alt=Page 12: OncologyPRO Educational Portal for Oncologistspatients with advanced NETS after progression on everolimus N 395 Well- or moderately-differentiated neuroendocrine Cabozantinib loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader034vdocumentssitereader034viewer20220504125f893dfa9e106f71164efef7html5thumbnails12jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=13Page 13button div class=ts-imageimg data-url=oncologypro-educational-portal-for-oncologists-patients-with-advanced-netshtmlpage=13 data-page=13 class=ts-thumb lazyload alt=Page 13: OncologyPRO Educational Portal for Oncologistspatients with advanced NETS after progression on everolimus N 395 Well- or moderately-differentiated neuroendocrine Cabozantinib loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader034vdocumentssitereader034viewer20220504125f893dfa9e106f71164efef7html5thumbnails13jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=14Page 14button div class=ts-imageimg data-url=oncologypro-educational-portal-for-oncologists-patients-with-advanced-netshtmlpage=14 data-page=14 class=ts-thumb lazyload alt=Page 14: OncologyPRO Educational Portal for Oncologistspatients with advanced NETS after progression on everolimus N 395 Well- or moderately-differentiated neuroendocrine Cabozantinib loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader034vdocumentssitereader034viewer20220504125f893dfa9e106f71164efef7html5thumbnails14jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=15Page 15button div class=ts-imageimg data-url=oncologypro-educational-portal-for-oncologists-patients-with-advanced-netshtmlpage=15 data-page=15 class=ts-thumb lazyload alt=Page 15: OncologyPRO Educational Portal for Oncologistspatients with advanced NETS after progression on everolimus N 395 Well- or moderately-differentiated neuroendocrine Cabozantinib loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader034vdocumentssitereader034viewer20220504125f893dfa9e106f71164efef7html5thumbnails15jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=16Page 16button div class=ts-imageimg data-url=oncologypro-educational-portal-for-oncologists-patients-with-advanced-netshtmlpage=16 data-page=16 class=ts-thumb lazyload alt=Page 16: OncologyPRO Educational Portal for Oncologistspatients with advanced NETS after progression on everolimus N 395 Well- or moderately-differentiated neuroendocrine Cabozantinib loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader034vdocumentssitereader034viewer20220504125f893dfa9e106f71164efef7html5thumbnails16jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=17Page 17button div class=ts-imageimg data-url=oncologypro-educational-portal-for-oncologists-patients-with-advanced-netshtmlpage=17 data-page=17 class=ts-thumb lazyload alt=Page 17: OncologyPRO Educational Portal for Oncologistspatients with advanced NETS after progression on everolimus N 395 Well- or moderately-differentiated neuroendocrine Cabozantinib loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader034vdocumentssitereader034viewer20220504125f893dfa9e106f71164efef7html5thumbnails17jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=18Page 18button div class=ts-imageimg data-url=oncologypro-educational-portal-for-oncologists-patients-with-advanced-netshtmlpage=18 data-page=18 class=ts-thumb lazyload alt=Page 18: OncologyPRO Educational Portal for Oncologistspatients with advanced NETS after progression on everolimus N 395 Well- or moderately-differentiated neuroendocrine Cabozantinib loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader034vdocumentssitereader034viewer20220504125f893dfa9e106f71164efef7html5thumbnails18jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=19Page 19button div class=ts-imageimg data-url=oncologypro-educational-portal-for-oncologists-patients-with-advanced-netshtmlpage=19 data-page=19 class=ts-thumb lazyload alt=Page 19: OncologyPRO Educational Portal for Oncologistspatients with advanced NETS after progression on everolimus N 395 Well- or moderately-differentiated neuroendocrine Cabozantinib loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader034vdocumentssitereader034viewer20220504125f893dfa9e106f71164efef7html5thumbnails19jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=20Page 20button div class=ts-imageimg data-url=oncologypro-educational-portal-for-oncologists-patients-with-advanced-netshtmlpage=20 data-page=20 class=ts-thumb lazyload alt=Page 20: OncologyPRO Educational Portal for Oncologistspatients with advanced NETS after progression on everolimus N 395 Well- or moderately-differentiated neuroendocrine Cabozantinib loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader034vdocumentssitereader034viewer20220504125f893dfa9e106f71164efef7html5thumbnails20jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=21Page 21button div class=ts-imageimg data-url=oncologypro-educational-portal-for-oncologists-patients-with-advanced-netshtmlpage=21 data-page=21 class=ts-thumb lazyload alt=Page 21: OncologyPRO Educational Portal for Oncologistspatients with advanced NETS after progression on everolimus N 395 Well- or moderately-differentiated neuroendocrine Cabozantinib loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader034vdocumentssitereader034viewer20220504125f893dfa9e106f71164efef7html5thumbnails21jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=22Page 22button div class=ts-imageimg data-url=oncologypro-educational-portal-for-oncologists-patients-with-advanced-netshtmlpage=22 data-page=22 class=ts-thumb lazyload alt=Page 22: OncologyPRO Educational Portal for Oncologistspatients with advanced NETS after progression on everolimus N 395 Well- or moderately-differentiated neuroendocrine Cabozantinib loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader034vdocumentssitereader034viewer20220504125f893dfa9e106f71164efef7html5thumbnails22jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=23Page 23button div class=ts-imageimg data-url=oncologypro-educational-portal-for-oncologists-patients-with-advanced-netshtmlpage=23 data-page=23 class=ts-thumb lazyload alt=Page 23: OncologyPRO Educational Portal for Oncologistspatients with advanced NETS after progression on everolimus N 395 Well- or moderately-differentiated neuroendocrine Cabozantinib loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader034vdocumentssitereader034viewer20220504125f893dfa9e106f71164efef7html5thumbnails23jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=24Page 24button div class=ts-imageimg data-url=oncologypro-educational-portal-for-oncologists-patients-with-advanced-netshtmlpage=24 data-page=24 class=ts-thumb lazyload alt=Page 24: OncologyPRO Educational Portal for Oncologistspatients with advanced NETS after progression on everolimus N 395 Well- or moderately-differentiated neuroendocrine Cabozantinib loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader034vdocumentssitereader034viewer20220504125f893dfa9e106f71164efef7html5thumbnails24jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=25Page 25button div class=ts-imageimg data-url=oncologypro-educational-portal-for-oncologists-patients-with-advanced-netshtmlpage=25 data-page=25 class=ts-thumb lazyload alt=Page 25: OncologyPRO Educational Portal for Oncologistspatients with advanced NETS after progression on everolimus N 395 Well- or moderately-differentiated neuroendocrine Cabozantinib loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader034vdocumentssitereader034viewer20220504125f893dfa9e106f71164efef7html5thumbnails25jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=26Page 26button div class=ts-imageimg data-url=oncologypro-educational-portal-for-oncologists-patients-with-advanced-netshtmlpage=26 data-page=26 class=ts-thumb lazyload alt=Page 26: OncologyPRO Educational Portal for Oncologistspatients with advanced NETS after progression on everolimus N 395 Well- or moderately-differentiated neuroendocrine Cabozantinib loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader034vdocumentssitereader034viewer20220504125f893dfa9e106f71164efef7html5thumbnails26jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=27Page 27button div class=ts-imageimg data-url=oncologypro-educational-portal-for-oncologists-patients-with-advanced-netshtmlpage=27 data-page=27 class=ts-thumb lazyload alt=Page 27: OncologyPRO Educational Portal for Oncologistspatients with advanced NETS after progression on everolimus N 395 Well- or moderately-differentiated neuroendocrine Cabozantinib loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader034vdocumentssitereader034viewer20220504125f893dfa9e106f71164efef7html5thumbnails27jpg width=140 height=200 divdiv
